Why Agios Pharmaceuticals Stock Is Up More Than 21% Today [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting. That's the overarching takeaway from this morning's press release anyway. As it explains, Agios' recent meeting with the U.S. Food and Drug Administration laid the groundwork for the "submission of a proposal for a confirmatory clinical trial to support U.S. accelerated approval of mitapivat." The company's already submitted the proposal for this abbreviated trial, in fact, and expects to submit its request for accelerated full approval to the FDA within the next few months. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The path for an accelerated approval is cleared Agios Pharmaceuticals' oral pyruvate kinase (PK) activator mitapivat is proving to be a capable multipurpose therapy. Already approved to tr
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals (AGIO) had its price target raised by The Goldman Sachs Group, Inc. from $28.00 to $32.00. They now have a "neutral" rating on the stock.MarketBeat
- Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & KorsinskyPR Newswire
- Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything [Yahoo! Finance]Yahoo! Finance
- AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost MoneyPR Newswire
- Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA [Yahoo! Finance]Yahoo! Finance
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 4/2/26 - Form 144
- 4/2/26 - Form 144
- 4/2/26 - Form 144
- AGIO's page on the SEC website